Biotech Startups

Ateria Health is a health and wellness company focused on gut microbiome health, developing products based on proprietary enzyme research to address conditions like irritable bowel syndrome. The company targets consumers seeking dietary supplements and health interventions related to digestive and metabolic health.

1 investor

AtG develops a pipeline of tumor adaptation inhibitors and biomarkers aimed at stopping cancer growth over time. It operates in oncology drug development within the biotech industry.

1 investor

Athaca provides AI-driven solutions for clinical trial management, including synthetic patient cohort generation for rare diseases, intelligent data quality analysis, and protocol design risk assessment. The platform operates in regulated healthcare environments with emphasis on data privacy, auditability, and compliance.

1 investor

1 investor

Athernal Bio develops targeted immunotherapies for high-risk clonal haematopoiesis, a blood cancer precursor condition, with the goal of training the immune system to detect and eliminate mutated stem cells before blood cancers such as AML emerge. The company works in oncology/biotech, focusing on early therapeutic intervention for blood cancer precursor conditions.

1 investor

Atlas Antibodies develops and supplies validated antibodies and reagents for life-science research, building on work from the Human Protein Atlas project. Its offerings target researchers running protein-detection experiments across tissues, with a focus on validation rigor and application support.

1 investor

Atlas Clinical operates as a clinical research site conducting FDA-regulated trials for pharmaceutical and biotechnology sponsors. The company recruits and manages volunteer participants through multi-phase in-human testing of new drug candidates and therapeutic devices.

1 investor

Atlas Molecular Pharma is a biotech spin-off that discovers first-in-class therapeutics based on pharmacological chaperones for rare and ultra-rare diseases, then licenses them to larger partners for commercialization. The company serves patients with rare and ultra-rare diseases and operates from Spain.

1 investor

Atmo Biosciences develops an FDA-cleared ingestible capsule using gas-sensing technology to diagnose gastrointestinal dysmotility conditions for gastroenterologists. The product provides objective clinical data to help manage treatment decisions and side effects in patients, particularly those experiencing gastrointestinal complications from GLP-1 weight loss medications.

1 investor

Atogen (에이투젠) researches the interactions between the human body and its microbiome and develops microbiome-based therapeutics that treat disease by restoring an imbalanced microbial flora. The company operates in the biotech and therapeutics space.

1 investor

Atomistic Insights combines physics-based modeling of protein dynamics with AI to study protein motion for drug discovery, aiming to address targets considered "undruggable." The company develops approaches intended to help drug developers reduce toxicity and expand the range of viable therapeutic targets.

1 investor

AtomVie is a contract development and manufacturing organization (CDMO) that provides cGMP manufacturing and global distribution of radiopharmaceuticals for diagnostic and therapeutic applications. The company serves clinical developers and commercial manufacturers advancing drugs through development toward commercialization.

1 investor

Atransen Pharma is a biotech company developing novel cancer treatments through LAT1 inhibitors and transporter-based drug discovery approaches. The company's research builds on amino acid transporter science from Osaka University and aims to create more effective cancer therapies with fewer side effects.

1 investor

1 investor

ATRO Medical is a Dutch clinical-stage orthopedic company developing the Artimis artificial meniscus implant (prosthesis) for patients with chronic knee pain after meniscectomy. Its device is being evaluated in clinical trials at Dutch hospitals and has received FDA breakthrough device designation.

1 investor

Attana develops analytical instruments and services based on interaction analysis of on- and off-target interactions to help validate, select, and optimize drug candidates for Phase I and Phase II studies. It serves the life science community, including pharmaceutical companies and academic research institutions.

1 investor

Attomarker develops rapid diagnostic technologies using nanophotonic testing for healthcare applications. The company, a University of Exeter spinout based in the UK, focuses on precise, real-world blood and health diagnostics.

1 investor

AuB develops gut microbiome research-backed healthcare products and services, primarily targeting athletes and the sports community. The company combines athlete microbiome data and AI analysis to create conditioning and health products aimed at optimizing personal performance and wellbeing.

1 investor

Audaxis Medical develops biocompatible pelvic health implants using next-generation biomaterials designed to integrate with the body and replace legacy materials. The company focuses on women's pelvic health solutions that prioritize safety, durability, and clinical efficacy.

1 investor

Audion Therapeutics is developing treatments for hearing restoration and related conditions by leveraging cellular regeneration research. The company focuses on pharmaceutical and therapeutic interventions for otology and auditory neurobiology.

1 investor

1 investor

SpaceOAR Hydrogel is a polyethylene glycol-based hydrogel spacer used during prostate cancer radiation therapy to reduce urinary, sexual, and bowel side effects. It is a medical device offered to prostate cancer patients and their physicians in the United States.

1 investor

Augurex develops and commercializes diagnostic tests for autoimmune conditions, with a focus on reducing diagnostic delays and enabling timely patient care. The company's offerings include tests for rheumatoid arthritis and axial spondyloarthritis.

1 investor

August Bioservices is a contract research, development, and manufacturing organization (CDMO) specializing in sterile injectables, offering end-to-end services from development to commercial manufacturing. It serves pharmaceutical and biotech companies developing novel therapeutics.

1 investor